Carfilzomib, lenalidomide and dexamethasone (KRd) versus elotuzumab-KRd as induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma: post-induction IMWG and MRD response of a randomized multicenter study-MedSci.cn

Carfilzomib, lenalidomide and dexamethasone (KRd) versus elotuzumab-KRd as induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma: post-induction IMWG and MRD response of a randomized multicenter study

Knop, S; Kull, M; Krönke, J; Drewniok, P; Schäfer-Eckart, K; Von, MI; Wolleschak, D; Kimmig, C; Greiner, J; Böttcher, S; Dechow, T; Hentrich, M; Khandanpour, C; Shumilov, E; Naumann, R; Seggewiss-Bernhardt, R; Hackanson, B; Wang, SY; Salwender, H; Sormann, S; Stübig, T; Brüggemann, M; Einsele, H

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Carfilzomib, lenalidomide and dexamethasone (KRd) versus elotuzumab-KRd as induction and consolidation in transplant-eligible patients with newly diagnosed multiple myeloma: post-induction IMWG and MRD response of a randomized multicenter study

科室

工具

服务